Loading clinical trials...
Loading clinical trials...
Prospective, Monocentric, Clinical Phase-I/II Study of the Effectiveness of the Percutaneous Irreversible Electroporation (IRE) of Locally Confined Kidney Tumors (Renal Cell Carcinomas).
The aim of the study is the evaluation of the ablation efficiency of the percutaneous irreversible electroporation (IRE) as primary ablation therapy of locally confined renal cell carcinoma (≤4cm, see inclusion and exclusion criteria). The ablation success will be proofed by magnet resonance imaging (MRI) and histologically after partial kidney resection or nephrectomy 4 weeks after IRE. Hypotheses: Kidney tumors ≤4cm can be ablated completely by percutaneous IRE. Surrounded structures and renal tissue can be preserved.
Health Condition or Problem studied: 1. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD10): C64 - Malignant neoplasm of kidney, except renal pelvis 2. ICD10: D41.0 - Neoplasm of uncertain or unknown behaviour: Kidney Interventions/Observational Groups Arm 1: 1. Initial diagnostical examination of the renal mass. 2. If any extended diagnostical examination for treatment planning. 3. Day -29 to -1: Recruitment. 4. Day -1: MRI of the kidney, Karnofsky, physical examination, blood chemistry, urosonography, if any renal scintigraphy, life quality assessment. 5. Day 0: Percutaneous diagnostical biopsy with histopathological investigation and therapeutically, CT- and/or ultrasound-guided, ECG-synchronized irreversible electroporation (IRE) of the kidney tumor in endotracheal anaesthesia und muscle relaxation. Use of 1-6 IRE probes with 90-100 pulses of 1500-3000 volts und 20-50 amperes each. 6. Day 1-7: Postinterventional follow-up: MRI of the kidneys, Karnofsky, physical examination, blood chemistry, urosonography, life quality assessment. 7. Day 27: Postinterventional follow-up: MRI of the kidneys, Karnofsky, physical examination, blood chemistry, urosonography, if any renal scintigraphy, life quality assessment. 8. Day 28: Open surgery partial kidney resection or tumor nephrectomy of the IRE treated kidney resp. kidney tumor region with histopathological investigation. 9. Day 29-37: Postoperative follow-up: physical examination, blood chemistry, urosonography, life quality assessment. 10. Day 112: Study-Follow-up: MRI of the kidneys, Karnofsky, physical examination, blood chemistry, urosonography, if any renal scintigraphy, life quality assessment. Termination of the study. 11. Study closed, Individual follow-up due to the European Association of Urology guideline. Recruitment: * (Anticipated or Actual) Date of First Enrollment: 2013/10/14 * Planned/Actual: Opened * Target Sample Size: 20 * Monocentric/Multicentric trial: Monocentric trial * National/International: National
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Department of Pathology University Hospital Otto-von-Guericke-University Magdeburg
Magdeburg, Saxony-Anhalt, Germany
Department of Radiology University Hospital Otto-von-Guericke-University Magdeburg
Magdeburg, Saxony-Anhalt, Germany
Department of Urology University Hospital Otto-von-Guericke-University Magdeburg
Magdeburg, Saxony-Anhalt, Germany
MVZ Hanse Histologikum GmbH Hamburg
Hamburg, Germany
Start Date
October 1, 2013
Primary Completion Date
December 1, 2015
Completion Date
January 1, 2016
Last Updated
November 19, 2014
20
ESTIMATED participants
Irreversible Electroporation (IRE)
PROCEDURE
Lead Sponsor
University of Magdeburg
NCT06391099
NCT06349642
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions